-
Mashup Score: 7Refining frailty in relapsed or refractory multiple myeloma: adding the patient voice - 2 year(s) ago
Multiple myeloma is an incurable haematological malignancy with a rapidly evolving treatment landscape. Despite novel therapies, ageing-associated vulnerabilities can complicate the treatment of older adults with this condition.1 The International Myeloma Working Group (IMWG) frailty score predicts treatment-related toxicity and mortality for older adults with newly diagnosed multiple myeloma. By…
Source: The Lancet Healthy LongevityCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1First-Line Bortezomib Associated With Increased Risk of Falls for Geriatric Multiple Myeloma - 3 year(s) ago
Elderly patients with multiple myeloma who were treated with first-line bortezomib had a higher risk of falls vs age-matched controls.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Elderly patients with multiple myeloma who were treated with first-line bortezomib had a higher risk of falls vs age-matched controls. #mmsm | @KellySchoenbeck https://t.co/xwls5sDGap
-
-
Mashup Score: 10Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study - 3 year(s) ago
PURPOSE Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a phase II trial specifically for frail patients, evaluating the efficacy and tolerability of ixazomib-daratumumab-low-dose-dexamethasone (Ixa-Dara-dex). METHODS Sixty-five patients, who were frail according to the International Myeloma…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
HOVON-143 prospective #MMsm study in frail NDMM: 👉 Age > 80 ≠ frail 👉 SCT-ineligible ≠ frail 👉 Frail = frail (IMWG scorable using online calculators) > 50% d/c'ed Tx 😞, partly PI-related neuropathy (fall risk per @KellySchoenbeck @tanyawildes ) https://t.co/h3gQvFrGHJ https://t.co/MK70t5YRwU
-
-
Mashup Score: 0Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma - 4 year(s) ago
Bortezomib is a common multiple myeloma therapy that can cause treatment-related peripheral neuropathy, a risk factor for falls. The relationship betw…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
So proud of @KellySchoenbeck & this project. We took clinical observation ("wow, did not expect this pt with myeloma to fall! Is it their treatment?") to the data & supported hypothesis: Receiving bortezomib ⬆️odds of falls 36% in Year 1. New in @JGeriOnc https://t.co/ayikTtfi69 https://t.co/K1ZtDHTlvh
-
-
Mashup Score: 2With Time on Your Side, the Sky’s the Limit: ASH Research Training Award for Fellows - ASH News Daily - 4 year(s) ago
The ASH Research Training Award for Fellows (RTAF) is an award open to both MD and MD/PhD researchers between their second and fifth year of fellowship designed to encourage junior researchers in hematology, hematology/oncology, and other hematology-related programs to pursue careers in academic hematology. RTAF provides each recipient with $70,000 for a one-year…
Source: ASH News DailyCategories: Hem/Oncs, Latest HeadlinesTweet-
Welcome to Twitter, @KellySchoenbeck ! She has been a great resource for us more-junior fellows at @HemoncUcsf and also someone to look up to as a winner of the @ASH_hematology RTAF award! https://t.co/zgaGHYcTBD https://t.co/u1tpv6qz0d
-
Love seeing my mentee @KellySchoenbeck find her niche in #gerionc: her commentary on a recent @LancetLongevity paper on relationship between PROs and frailty in older adults with #myeloma #mmsm https://t.co/p8eCwq40MY https://t.co/FzmjIu7VNo